These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 2483715

  • 1. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
    Harenberg J, Stehle G, Dempfle CE, von Hodenberg E, Heene DL.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
    [Abstract] [Full Text] [Related]

  • 2. Comparative human pharmacology of low molecular weight heparins.
    Harenberg J, Stehle G, Augustin J, Zimmermann R.
    Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
    [Abstract] [Full Text] [Related]

  • 3. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin).
    Persson E.
    Acta Med Scand Suppl; 1988 Oct; 724():1-56. PubMed ID: 2843005
    [Abstract] [Full Text] [Related]

  • 4. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J, Stehle G, Blauth M, Huck K, Mall K, Heene DL.
    Semin Thromb Hemost; 1997 Oct; 23(1):83-90. PubMed ID: 9156415
    [Abstract] [Full Text] [Related]

  • 5. Pharmacology of low molecular weight heparins.
    Harenberg J.
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():12-8. PubMed ID: 1962899
    [Abstract] [Full Text] [Related]

  • 6. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins.
    Harenberg J, Siegele M, Dempfle CE, Stehle G, Heene DL.
    Thromb Haemost; 1993 Dec 20; 70(6):942-5. PubMed ID: 8165616
    [Abstract] [Full Text] [Related]

  • 7. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M, Weltermann A, Nieszpaur-Los M, Schneider B, Fassolt A, Lechner K, Eichler HG, Kyrle PA.
    Thromb Haemost; 1995 Mar 20; 73(3):439-43. PubMed ID: 7667826
    [Abstract] [Full Text] [Related]

  • 8. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers.
    Harenberg J, Giese C, Dempfle CE, Stehle G, Heene DL.
    Thromb Haemost; 1989 Jun 30; 61(3):357-62. PubMed ID: 2552604
    [Abstract] [Full Text] [Related]

  • 9. Anticoagulant and lipolytic effects of a low molecular weight heparin fraction.
    Harenberg J, Gnasso A, de Vries JX, Zimmermann R, Augustin J.
    Thromb Res; 1985 Sep 15; 39(6):683-92. PubMed ID: 4082106
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of low molecular weight heparin by protamine chloride in vivo.
    Harenberg J, Gnasso A, de Vries JX, Zimmermann R, Augustin J.
    Thromb Res; 1985 Apr 01; 38(1):11-20. PubMed ID: 4002198
    [Abstract] [Full Text] [Related]

  • 11. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
    Grimaudo V, Omri A, Kruithof EK, Hauert J, Bachmann F.
    Thromb Haemost; 1988 Jun 16; 59(3):388-91. PubMed ID: 2847348
    [Abstract] [Full Text] [Related]

  • 12. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
    Ofosu FA, Smith LM, Anvari N, Blajchman MA.
    Thromb Haemost; 1988 Oct 31; 60(2):193-8. PubMed ID: 2851191
    [Abstract] [Full Text] [Related]

  • 13. Time-course of anti-Xa effects of calcium heparin and low-molecular-weight heparin given s.c.: insights for thrombosis prevention.
    Romeo G, Salanitri G, Catania G.
    Drugs Exp Clin Res; 1988 Oct 31; 14(6):423-7. PubMed ID: 2850903
    [Abstract] [Full Text] [Related]

  • 14. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D, Dawes J.
    Thromb Haemost; 1997 Feb 31; 77(2):317-22. PubMed ID: 9157589
    [Abstract] [Full Text] [Related]

  • 15. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
    Barrowcliffe TW, Thomas DP.
    Acta Chir Scand Suppl; 1988 Feb 31; 543():57-64. PubMed ID: 2847459
    [Abstract] [Full Text] [Related]

  • 16. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
    Drozd NN, Tolstenkov AS, Bannikova GE, Miftakhova NT, Lapikova ES, Makarov VA, Varlamov VP.
    Eksp Klin Farmakol; 2007 Feb 31; 70(6):19-24. PubMed ID: 18318190
    [Abstract] [Full Text] [Related]

  • 17. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats.
    Diness V, Ostergaard PB.
    Thromb Haemost; 1986 Dec 15; 56(3):318-22. PubMed ID: 3563964
    [Abstract] [Full Text] [Related]

  • 18. Neutralization of enoxaparine-induced bleeding by protamine sulfate.
    Van Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR.
    Thromb Haemost; 1990 Apr 12; 63(2):271-4. PubMed ID: 2163553
    [Abstract] [Full Text] [Related]

  • 19. Neutralization of the anticoagulant activity of low molecular weight heparin LU 47311 (Clivarin) in man by protamine chloride.
    Andrassy K, Eschenfelder V, Weber E.
    Thromb Res; 1994 Jan 15; 73(2):85-93. PubMed ID: 8171416
    [Abstract] [Full Text] [Related]

  • 20. [Neutralization of low molecular weight heparin Kabi 2165 by protamine chloride].
    Harenberg J, Giese C, Knödler A, Zimmermann R, Schettler G.
    Klin Wochenschr; 1986 Nov 17; 64(22):1171-5. PubMed ID: 3807263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.